Roquefort Therapeutics (LSE:ROQ) Total Assets : £6.09 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Total Assets?

Roquefort Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was £6.09 Mil.

During the past 12 months, Roquefort Therapeutics's average Total Assets Growth Rate was 2.00% per year.

Total Assets is connected with ROA %. Roquefort Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -29.13%. Total Assets is also linked to Revenue through Asset Turnover. Roquefort Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Roquefort Therapeutics Total Assets Historical Data

The historical data trend for Roquefort Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Total Assets Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Assets

4.56

7.77

6.09

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Total Assets	0.89	4.76	7.77	7.12	6.09

Roquefort Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Roquefort Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	5.5	+	0.589
	=	6.09

Roquefort Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	5.5	+	0.589
	=	6.09

Roquefort Therapeutics (LSE:ROQ) Total Assets Explanation

Total Assets is connected with ROA %.

Roquefort Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-1.924	/	( (7.121	+	6.089)	/ 2 )
	=	-1.924	/	6.605
	=	-29.13 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Roquefort Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (7.121	+	6.089)	/ 2 )
=	0	/	6.605
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Roquefort Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines